SCHEMBL2497117

SCHEMBL2497117

CCCCOc1ccc(OC)cc1Br

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.51
MAPT P10636 5/20 0.51
HPGD P15428 4/20 0.51
TDP1 Q9NUW8 4/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
LMNA P02545 2/20 0.49
MAPK1 P28482 1/20 0.49
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
GAA P10253 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2C9 P11712 1/20 0.46
AHR P35869 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31456048 0.93 MTNR1A (0.48) L3MBTL1MAPTHPGDTDP1SMN1; SMN2
SCHEMBL27710358 0.91 MAPT (0.49) L3MBTL1MAPTHPGDTDP1SMN1; SMN2
SCHEMBL27810349 0.87 AHR (0.45) L3MBTL1MAPTHPGDTDP1SMN1; SMN2
SCHEMBL28018164 0.86 THRA (0.52) TSHRTHRATHRB
SCHEMBL8000546 0.86 THRA (0.52) TSHRTHRATHRB
SCHEMBL3720086 0.85 L3MBTL1 (0.47) L3MBTL1MAPTHPGDTDP1SMN1; SMN2
SCHEMBL17260308 0.85 MAPT (0.50) L3MBTL1MAPTHPGDTDP1SMN1; SMN2
SCHEMBL13303518 0.84 TDP1 (0.48) L3MBTL1MAPTHPGDTDP1SMN1; SMN2
SCHEMBL17733188 0.84 MTNR1A (0.44) L3MBTL1MAPTHPGDTDP1SMN1; SMN2
SCHEMBL5722672 0.84 L3MBTL1 (0.46) L3MBTL1MAPTHPGDTDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139843-B1 SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS AMGEN INC (US) 2013-12-25 EP disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
EP-2205548-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS Amgen, Inc (US) 2010-07-14 EP disclosed
EP-2139843-A1 SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS Amgen, Inc (US) 2010-01-06 EP disclosed
US-7572934-B2 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-08-11 US disclosed
US-7572934-B2 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-08-11 US disclosed
US-7572934-B2 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-08-11 US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed
US-20090111859-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-04-30 US disclosed
US-20090111859-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-04-30 US disclosed
US-20090111859-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-04-30 US disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 WO disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 WO disclosed
WO-2008130514-A1 SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS AMGEN INC. (US) 2008-10-30 WO disclosed
WO-2008130514-A1 SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS AMGEN INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137561-A1 Substituted biphenyl GPR40 modulators GPR119, GPR65, GPR55 L3MBTL1 4560/4885MAPT 4550/4885HPGD 1586/4885
US-20090111859-A1 Substituted biphenyl GPR40 modulators GPR119, GPR65, GPR55 L3MBTL1 4560/4885MAPT 4550/4885HPGD 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.